Selvita bridges Krakow and San Francisco
The company has officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of US.
Selvita, the largest drug discovery company in Central and Eastern Europe, has just opened its West Coast US office, located in San Bruno, CA.
Selvita initiated its US operations in September 2015, opening a fully-owned US subsidiary, Selvita Inc., headquartered in Cambridge, MA. Now the company is officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of US.
“The US drug discovery market is absolutely strategic for Selvita. It is not only where most of our revenue comes from, but also where we put most of our hopes in," said Pawel Przewiezlikowski, CEO at Selvita.
"We are continuously investing in top class-facilities and best professionals. In 2016 we are opening our second research facility in Poznan, Poland, and we believe we have even more to offer to our customers.
"The last several months of our operations on the US East Coast, have shown that our local presence is not only bringing us closer to our US clients, but also facilitating a more swift bidirectional transfer of know-how between our labs in Poland and the partner base in the US.
Having two US offices located in where the heart of the biotechnology industry beats — in Greater Boston and in the San Francisco Bay areas — is what will definitely bring us closer to achieving our goal of becoming the drug discovery partner of choice for the US biotech and pharma industry.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.